AX-2026-043640

BPC-157 · 10 mg declared · WuXi TIDES (WuXi AppTec Testing Division) · lot WXT-2508-E6361

PASSVERIFIED

Report ID: AX-2026-043640
Compound: BPC-157
Compound class: Tissue-repair and immunomodulatory peptides
Supplier: WXT — WuXi TIDES (WuXi AppTec Testing Division)
Batch / lot: WXT-2508-E6361
Declared label claim: 10mg
Laboratory: Janoshik Analytical
Assay date: 28 Feb 2026
Submitted: 10 Mar 2026
Quarter: 2026-Q1
Submitter: fa.sjoberg
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	98.05	% area	≥ 98.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.95	% area	≤ 2.0	PASS
Largest single impurity	RP-HPLC — [D-Val]-diastereomer	0.96	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	1418.7093	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	1418.7076	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-1.2	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	88.12	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	86.40	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	11.17	mg	10 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	9.651	mg	10 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	96.5	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	3.54	%	≤ 10.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	8.06	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.28	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.71	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White cake, partial shrinkage from vial wall	—	white to off-white intact cake	FAIL
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.53	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	9.60	min	9.62 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.86	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	75,877	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Val]-diastereomer	0.98	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 75,877, and skew follows the reported asymmetry factor of 0.86. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.96 % impurity against a 98.05 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	BPC-157 — main peak	9.60	4,765,534	98.05	—
2	[D-Val]-diastereomer	9.46	46,659	0.96	0.000
3	acetylated N-terminus (+42 Da)	10.08	22,357	0.46	+42.011
4	pyroglutamate cyclisation (−17 Da)	9.91	12,637	0.26	-17.027
5	des-Gly truncate (−57 Da)	9.26	8,263	0.17	-57.021
6	BPC-157 arginine-salt artefact	9.05	3,402	0.07	0.000
7	truncated (1-12)	8.64	1,458	0.03	-285.132
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 1418.7093 Da, computed from C62H98N16O22. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 1418.7076 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
3+	473.9104	473.9098	-0.0006	8.5
2+	710.3619	710.3611	-0.0008	56.4
1+	1419.7166	1419.7149	-0.0017	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	3.54
Counter-ion (acetate)	ion chromatography	8.06
Residual solvent + inorganic residue	estimated	0.28
Total peptide content	by difference	88.12
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.10	98.05	divergence +0.04 pp vs batch median
Total impurities (% area)	not stated	1.95
Largest single impurity (% area)	not stated	0.96
Water (%)	2.9	3.54
Counter-ion (%)	7.4	8.06
Peptide content (%w/w)	89.1	88.12
Endotoxin (EU/mg)	not stated	0.71
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 19 d) → laboratory (hand-carried, 9 d) → assay.
Assay date: 28 Feb 2026
Submitted to the index: 10 Mar 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot WXT-2508-E6361 n=5

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043636	WXT-2508-E6361	Janoshik	2026-Q1	97.95	3.50	—	Buyer-sourced	0	FAIL
AX-2026-043637	WXT-2508-E6361	PeptideMeter	2026-Q1	98.06	4.56	96.4	Buyer-sourced	1	FAIL
AX-2026-043638	WXT-2508-E6361	Janoshik	2026-Q1	98.53	4.28	106.1	Supplier-supplied	0	PASS
AX-2026-043639	WXT-2508-E6361	Janoshik	2026-Q1	98.82	4.23	96.7	Supplier-supplied	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent BPC-157 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043691	BCH	BCH-2603-L7768	Janoshik	2026-Q3	98.66	5.12	—	Supplier-supplied	1	MARGINAL
AX-2026-043493	CPC	CPC-2602-W3201	Janoshik	2026-Q3	98.76	2.27	—	Buyer-sourced	2	FAIL
AX-2026-041387	WWB	WWB-2606-H3906	Janoshik	2026-Q3	99.33	4.64	—	Laboratory-retained	0	PASS
AX-2026-043693	BCH	BCH-2603-L7768	PeptideMeter	2026-Q3	97.82	5.21	94.9	Buyer-sourced	0	FAIL
AX-2026-043686	BCH	BCH-2603-L7768	VendorInvestigate	2026-Q3	97.64	5.27	—	Buyer-sourced	0	FAIL
AX-2026-043695	BCH	BCH-2603-L7768	Janoshik	2026-Q3	97.61	5.42	—	Buyer-sourced	0	FAIL
AX-2026-043487	CPC	CPC-2602-W3201	VendorInvestigate	2026-Q3	99.07	2.76	97.0	Laboratory-retained	1	MARGINAL
AX-2026-041385	WWB	WWB-2606-H3906	Medutest	2026-Q3	99.29	4.43	—	Buyer-sourced	0	PASS

Other recent WXT records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043651	Pramlintide	WXT-2603-D6459	PeptideMeter	2026-Q3	98.21	4.97	101.6	Buyer-sourced	1	MARGINAL
AX-2026-043531	Leuprolide	WXT-2604-K4483	Medutest	2026-Q3	99.00	5.03	—	Buyer-sourced	0	PASS
AX-2026-043561	Semaglutide	WXT-2604-C5135	Janoshik	2026-Q3	96.96	4.22	91.3	Buyer-sourced	0	FAIL
AX-2026-043627	L-Glutathione (reduced)	WXT-2605-B5720	Janoshik	2026-Q3	97.96	6.08	92.3	Buyer-sourced	1	FAIL
AX-2026-043564	Semaglutide	WXT-2604-C5135	Janoshik	2026-Q3	97.15	4.44	104.7	Buyer-sourced	0	PASS
AX-2026-043533	Leuprolide	WXT-2604-K4483	PeptideMeter	2026-Q3	99.89	4.94	—	Supplier-supplied	0	PASS
AX-2026-043624	L-Glutathione (reduced)	WXT-2605-B5720	Nordanalyt	2026-Q3	98.18	6.95	105.3	Buyer-sourced	2	FAIL
AX-2026-043556	Semaglutide	WXT-2604-C5135	PeptideMeter	2026-Q3	97.56	4.35	89.6	Buyer-sourced	1	MARGINAL